Navigation Links
Value-Line Oxygen Flowmeters

ProductsValue-Line Oxygen Flowmeters
Company Western Medica
Item Value-Line Oxygen Flowmeters
Features 
  • Calibrated at 50 psi inlet
  • Optional power take-off units provide 50 psi additional outlet pressure
  • Double units for multi-patient use from one wall outlet
    • Description Value-Line oxygen flowmeters.
    Options:
  • For security chain, add suffix S to model number. Example: FMQ107S.
  • For Canadian Color-Code, add suffix FMQ104C.
  • For Double Flowmeters with Power Take-Off, add PT to model number. Example: FMQPT409.
    • Info Western Medica
    Customer Service: (800) 783-7890
    Web site: http://www.westernmedica.com/

    Related medicine products :

    1. Value-Line Oxygen Power Take Off Flowmeters
    2. Value-Line Oxygen Double Flowmeters
    3. LICOX Brain Tissue Oxygen Monitoring System
    4. PULSOX-2 Oxygen Saturation Monitor
    5. LOTUS™ Electronic Oxygen Conserver (with alarm)
    6. OXYMATIC® 401 Electronic Oxygen Conserver
    7. LOTUS™ Electronic Oxygen Conserver (without alarm)
    8. OXYMATIC® 401A Electronic Oxygen Conserver
    9. OXYMATIC® 411A Electronic Oxygen Conserver
    10. OXYMATIC® 411 Electronic Oxygen Conserver
    11. OXYMATIC® 411AF Electronic Oxygen Conserver
    Breaking Medicine News(10 mins):Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3Health News:VHI Releases Annual Industry Report - Highlights Hospital, Nursing Facility Efficiency 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 3Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6
    Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Mesa Labs Increases Quarterly Dividend 61255 1Neogen to Ring NASDAQs Closing Bell 14815 1Neogen to Ring NASDAQs Closing Bell 14815 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 1Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 3